We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Living Cell Technologies is a biotechnology business based in Australia. Living Cell Technologies shares (LCT) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Living Cell Technologies has a trailing 12-month revenue of around $155,368. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
Overall broker
Our top pick for
Low-cost broker
| 52-week range | $0.0045 - $0.016 |
|---|---|
| 50-day moving average | $0.0065 |
| 200-day moving average | $0.0068 |
| Target price | N/A |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.003 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.009
| 1 week (2022-06-29) | 0.009 |
|---|---|
| 1 month (2022-06-06) | 28.57% |
| 3 months (2022-04-06) | 28.57% |
| 6 months (2022-01-06) | 80.00% |
| 1 year (2021-07-06) | -35.71% |
|---|---|
| 2 years (2020-07-06) | -40.00% |
| 3 years (2019-07-05) | -60.87% |
| 5 years (2017-07-06) | -91.43% |
| Revenue TTM | $155,368 |
|---|---|
| Gross profit TTM | $268,184 |
| Return on assets TTM | -24.03% |
| Return on equity TTM | -48.81% |
| Profit margin | 0% |
| Book value | 0.004 |
| Market capitalisation | $11.6 million |
TTM: trailing 12 months
We're not expecting Living Cell Technologies to pay a dividend over the next 12 months.
Over the last 12 months, Living Cell Technologies 's shares have ranged in value from as little as $0.0045 up to $0.016. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Living Cell Technologies 's is 0.7102. This would suggest that Living Cell Technologies 's shares are less volatile than average (for this exchange).
Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was founded in 1987 and is based in Sydney, Australia.
Everything we know about the Octava Minerals IPO, plus information on how to buy in.
Everything we know about the Australia Sunny Glass Group IPO, plus information on how to buy in.
Steps to owning and managing Kincora Copper shares.
Everything we know about the Dragon Mountain Gold IPO, plus information on how to buy in.
Steps to owning and managing Arcadia Minerals shares.
Steps to owning and managing Nexgen Energy shares.
Steps to owning and managing Keypath Education shares.
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
Steps to owning and managing EBR Systems shares.
